英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Gilead Sciences Announces Completion of Acquisition of CymaBay
    “The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences
  • Gileads CEO Daniel ODay Projects Robust Growth in 2024 Amidst . . .
    Gilead Sciences, Inc (Nasdaq: GILD) announced today its first quarter 2024 results of operations “Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
  • CymaBay board pushed for 50 cent top up to Gileads $32. 50 offer
    CymaBay board pushed for 50 cent top up to Gilead's $32 50 per share offer By Annalee Armstrong Feb 26, 2024 10:49am Gilead Sciences CymaBay Therapeutics Daniel O'Day mergers and acquisitions
  • Gilead concludes acquisition of CymaBay Therapeutics for $4. 3bn
    Gilead Sciences chairman and CEO Daniel O’Day stated: “The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis “I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet need
  • Gilead Sciences Announces Third Quarter 2024 Financial Results
    Based on this very strong topline growth and disciplined operating expense management, we are increasing our full year revenue, operating income, and earnings per share guidance,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer “We are excited to further increase our impact for patients and communities in the months ahead
  • Gilead agrees $4. 3bn CymaBay deal — Financier Worldwide
    This will complement Gilead’s existing liver portfolio and aligns with its commitment to bringing transformational medicines to patients “We are looking forward to advancing seladelpar by leveraging Gilead’s long-standing expertise in treating and curing liver diseases,” said Daniel O’Day, chairman and chief executive of Gilead Sciences
  • Gilead, in latest cancer bet, puts $275M into immunotherapy startup . . .
    The investment extends a streak of dealmaking by Gilead in oncology, a renewed focus for the company under CEO Daniel O’Day In just over three months, the California-based biotech has thrown more than $5 5 billion at companies developing immune therapies to fight cancer in a bid to diversify its pipeline away from antiviral drugs
  • Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay . . .
    Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U S Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead
  • Gilead ups its US investment plans by $11 billion
    In a commentary on the investment, Gilead chief executive Daniel O'Day said that the company already carries out most of its R D within the US and has "been increasing our investment in US
  • Gilead Sciences CEO on Companys Evolution and Commitment to the Bay Area
    NORTHAMPTON, MA ACCESSWIRE March 5, 2024 Gilead SciencesOriginally published by SAN FRANCISCO BUSINESS TIMES on bizjournals com Much has changed since Daniel O'Day, chairman and CEO, arrived
  • Gilead pays $4. 3B for CymaBays late-stage liver disease med
    Gilead is bolstering its liver disease portfolio with the $4 3 billion acquisition of CymaBay, specifically for the liver disease med seladelpar
  • Gilead Sciences Announces Completion of Acquisition of CymaBay
    “The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences “I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet need





中文字典-英文字典  2005-2009